Health Products

Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concerns

· Published by Health Canada · Official notice

Details

Alert type: Public advisory
Category: Health products - Drugs
Product: All lots of Accel-Ondansetron ODT (4 mg and 8 mg tablets); Mint-Betahistine (8 mg, 16 mg and 24 mg tablets); PMS-Pirfenidone (267 mg and 801 mg tablets)
Issue: Health products - Product safety
What to do: Return the affected products to your local pharmacy for a replacement, and for proper disposal. If you are unsure whether your product is affected, check with your pharmacy. Consult a health care professional if you have used the affected product and you have health concerns.
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

LotDINProductExpiry
E0802A
E0802C
02531534PMS-Pirfenidone 801 mg tablets12-2024
2330706A
2430154
02538156Mint-Betahistine 24 mg tablets07-2025
01-2026
E0800A
E0800C
E0800E
E0800F
02531526PMS-Pirfenidone 267 mg tablets11-2024
2330704
2430152
02538121Mint-Betahistine 8 mg tablets07-2025
01-2026
2330705
2330945
2330946
2330947
2430153
02538148Mint-Betahistine 16 mg tablets07-2025
10-2025
10-2025
10-2025
01-2026
CDX0012302535319Accel-Ondansetron ODT 4 mg tablets09-2026
CEA0012302535327Accel-Ondansetron ODT 8 mg tablets09-2026

Issue

UPDATE: June 17, 2025 - Accel Pharma can resume sale of undistributed units of lots CDX00123 and CEA00123 after bioequivalence test data confirm Accel-Ondansetron ODT is safe and effective to use

After reviewing the bioequivalence test data provided by Accel Pharma Inc., Health Canada has confirmed that Accel-Ondansetron ODT (4 mg and 8 mg tablets) are equivalent to their brand name counterparts and are safe and effective to use. As a result, the company has resumed the sale of undistributed units from lots CDX00123 and CEA00123 (listed above).

Original Advisory: June 7, 2024

Three companies (Accel Pharma Inc., Mint Pharmaceuticals Inc., and Pharmascience Inc.) are recalling all lots listed in the Affected Products table (above) due to concerns about the integrity of tests that are used to show that their generic prescription drugs work the same as brand-name versions.

Health Canada's authorization of the affected products relied on the bioequivalence test data. Bioequivalence data is used to demonstrate that generic drugs are equivalent to their brand-name counterparts.

The bioequivalence tests were conducted by Synapse Labs Pvt. Ltd., a contract research organization in Pune, Maharashtra, India. An inspection by a member of the European Medicines Agency, a trusted regulatory partner, found that data produced by Synapse Labs can no longer be relied upon to show this bioequivalence. As a result, the affected products can no longer be considered safe and effective. At Health Canada's request, the companies have stopped sale and have recalled all lots of the affected products until they can provide additional information to demonstrate that the products are safe and effective.

Health Canada is monitoring the effectiveness of the recalls and will take appropriate and timely action if any new health risks are identified.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime